Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

BACKGROUND: To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood. METHO...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ribas, Antoni, Kirkwood, John M, Atkins, Michael B, Whiteside, Theresa L, Gooding, William, Kovar, Andreas, Gillies, Stephen D, Kashala, Oscar, Morse, Michael A
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2009
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2724499/
https://ncbi.nlm.nih.gov/pubmed/19640287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-7-68
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars